Rigel Pharmaceuticals Inc (RIGL) financials
Rigel Pharmaceuticals revenue and earnings by year
Rigel Pharmaceuticals's revenue was $294 million in the fiscal year to December 31, 2025, up 64.1% from the year before. Net income was $367 million, 124.7% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 34.5% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 294 | 179 | 117 | 120 | 149 | 109 | 59 | 45 | 4 | 20 |
| Revenue growth | 64.1% | 53.4% | -2.8% | -19.4% | 37.4% | 83.2% | 33.2% | 892.6% | -78.0% | — |
| Gross profit | 275 | 161 | 110 | 118 | 148 | 108 | 58 | 44 | — | — |
| Gross margin | 93.3% | 89.6% | 93.9% | 98.5% | 99.3% | 99.2% | 98.5% | 99.4% | — | — |
| Operating income | 125 | 24 | -20 | -56 | -12 | -29 | -69 | -73 | -79 | -70 |
| Operating margin | 42.6% | 13.5% | -17.5% | -46.2% | -8.4% | -26.7% | -116.5% | -163.3% | -1759.2% | -341.7% |
| Net income | 367 | 17 | -25 | -59 | -18 | -30 | -67 | -70 | -78 | -69 |
| Net margin | 124.7% | 9.8% | -21.5% | -48.7% | -12.0% | -27.4% | -112.8% | -158.3% | -1739.3% | -339.6% |
| Diluted EPS | $19.48 | $0.99 | -$1.44 | -$3.44 | -$1.10 | -$1.80 | — | — | — | — |
| Free cash flow | 76 | 31 | -20 | -74 | 5 | -53 | -43 | -60 | -78 | -77 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open RIGL in Markets.
How Rigel Pharmaceuticals makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Gross Product | $88.5M | 88.3% |
| Royalty Delivery Of Drug Supplies & Others | $7.69M | 7.7% |
| Development Milestones | $4.00M | 4.0% |
See also: RIGL valuation and P/E history · RIGL returns
No forecast, no recommendation. This page describes Rigel Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.